101 related articles for article (PubMed ID: 9155715)
1. E-cadherin quantitative immunocytochemical assays in breast carcinomas.
Charpin C; Garcia S; Bouvier C; Devictor B; Andrac L; Choux R; Lavaut M
J Pathol; 1997 Mar; 181(3):294-300. PubMed ID: 9155715
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer.
Gonzalez MA; Pinder SE; Wencyk PM; Bell JA; Elston CW; Nicholson RI; Robertson JF; Blamey RW; Ellis IO
J Pathol; 1999 Apr; 187(5):523-9. PubMed ID: 10398116
[TBL] [Abstract][Full Text] [Related]
3. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays.
Charpin C; Garcia S; Bonnier P; Martini F; Andrac L; Horschowski N; Lavaut MN; Allasia C
J Pathol; 1998 Apr; 184(4):401-7. PubMed ID: 9664906
[TBL] [Abstract][Full Text] [Related]
5. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features.
Palacios J; Benito N; Pizarro A; Suárez A; Espada J; Cano A; Gamallo C
Am J Pathol; 1995 Mar; 146(3):605-12. PubMed ID: 7534041
[TBL] [Abstract][Full Text] [Related]
6. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors.
Charpin C; Devictor B; Bonnier P; Andrac L; Lavaut MN; Allasia C; Piana L
J Pathol; 1993 Aug; 170(4):463-70. PubMed ID: 8410496
[TBL] [Abstract][Full Text] [Related]
8. E-cadherin expression in invasive breast cancer.
Suciu C; Cîmpean AM; Mureşan AM; Izvernariu D; Raica M
Rom J Morphol Embryol; 2008; 49(4):517-23. PubMed ID: 19050801
[TBL] [Abstract][Full Text] [Related]
9. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer.
Harigopal M; Berger AJ; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2005 Jun; 11(11):4083-9. PubMed ID: 15930343
[TBL] [Abstract][Full Text] [Related]
10. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer.
Lipponen P; Saarelainen E; Ji H; Aaltomaa S; Syrjänen K
J Pathol; 1994 Oct; 174(2):101-9. PubMed ID: 7965405
[TBL] [Abstract][Full Text] [Related]
11. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer.
Yoshida R; Kimura N; Harada Y; Ohuchi N
Int J Oncol; 2001 Mar; 18(3):513-20. PubMed ID: 11179480
[TBL] [Abstract][Full Text] [Related]
12. Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.
Izumi T; Oda Y; Hasegawa T; Nakanishi Y; Kawai A; Sonobe H; Takahira T; Kobayashi C; Yamamoto H; Tamiya S; Hirohashi S; Iwamoto Y; Tsuneyoshi M
Am J Surg Pathol; 2007 Jan; 31(1):85-94. PubMed ID: 17197923
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance.
Rakha EA; Abd El Rehim D; Pinder SE; Lewis SA; Ellis IO
Histopathology; 2005 Jun; 46(6):685-93. PubMed ID: 15910600
[TBL] [Abstract][Full Text] [Related]
14. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807
[TBL] [Abstract][Full Text] [Related]
15. Cadherins as predictive markers of nodal metastasis in breast cancer.
Madhavan M; Srinivas P; Abraham E; Ahmed I; Mathew A; Vijayalekshmi NR; Balaram P
Mod Pathol; 2001 May; 14(5):423-7. PubMed ID: 11353052
[TBL] [Abstract][Full Text] [Related]
16. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis.
Oka H; Shiozaki H; Kobayashi K; Inoue M; Tahara H; Kobayashi T; Takatsuka Y; Matsuyoshi N; Hirano S; Takeichi M
Cancer Res; 1993 Apr; 53(7):1696-701. PubMed ID: 8453644
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival.
Guriec N; Marcellin L; Gairard B; Caldéroli H; Wilk A; Renaud R; Bergerat JP; Oberling F
Invasion Metastasis; 1996; 16(1):19-26. PubMed ID: 8830762
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of activated Akt expression in oral squamous cell carcinoma.
Lim J; Kim JH; Paeng JY; Kim MJ; Hong SD; Lee JI; Hong SP
J Clin Pathol; 2005 Nov; 58(11):1199-205. PubMed ID: 16254112
[TBL] [Abstract][Full Text] [Related]
19. Abnormal expression of E-cadherin and beta-catenin may be a molecular marker of submucosal invasion and lymph node metastasis in early gastric cancer.
Tanaka M; Kitajima Y; Edakuni G; Sato S; Miyazaki K
Br J Surg; 2002 Feb; 89(2):236-44. PubMed ID: 11856141
[TBL] [Abstract][Full Text] [Related]
20. [Expression of Ezrin and E-cadherin in invasive ductal breast cancer and their correlations to lymphatic metastasis].
Li Q; Wu MF; Song AP; Wei JC; Xu G; Lu YP; Ma D
Ai Zheng; 2006 Mar; 25(3):363-6. PubMed ID: 16536996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
